This study sought to explore the prevalence of BRAF V600E mutation and CDKN2A deletion in pediatric patients with high-grade glioma (HGG) and aimed to add to the scarce data in the literature about the prognosis of this subset of patients treated with traditional surgery, radiation and chemotherapy. The gene discussed is CDKN2A; the disease is glioma.